| Date Filed | Type | Description |
| 08/22/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 08/22/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/18/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 08/11/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 08/10/2023 |
8-K
| Quarterly results|
Docs:
|
"ProKidney Reports Second Quarter Financial Results and Recent Corporate Highlights WINSTON-SALEM, N.C. – August 10, 2023 – ProKidney Corp. , a leading late clinical-stage cellular therapeutics company focused on dialysis-free living for those with chronic kidney disease , today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments. “In the second quarter, and throughout the first half of 2023, we steadily advanced our REACT development programs, including our initial Phase 3 study, proact 1, that is assessing the potential for REACT to delay or halt the progression of moderate to severe diabetic CKD,” said Dr. Tim Bertram, Chief Executive Officer of ProKidney. “Looking ahead, we expect to reach s..." |
|
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/25/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 07/18/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"ProKidney Announces Closing of Purchase of Manufacturing Facility in Greensboro, NC WINSTON-SALEM, N.C., July 18, 2023 — ProKidney Corp. , a leading late clinical-stage cellular therapeutics company focused on preserving kidney function in patients suffering from chronic kidney disease , today announced it has closed on its purchase of a 210,000 square foot facility and approximately 22 acres of land in Greensboro, N.C. ProKidney paid approximately $25.5 million in cash for the facility and property. The Company plans to make investments in the facility through 2028 to prepare for potential commercial-scale manufacturing of REACT®, its proprietary REnal Autologous Cell Therapy, currently in Phase 3 development for the treatment of diabetic CKD. In connection with the purchase, the city of ..." |
|
| 07/06/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 06/30/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 06/16/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"ProKidney Announces Purchase of Manufacturing Facility in Greensboro, NC WINSTON-SALEM, N.C., June 13, 2023 — ProKidney Corp. , a leading late clinical-stage cellular therapeutics company focused on preserving kidney function in patients suffering from chronic kidney disease , today announced its agreement to purchase a 210,000 square foot facility and approximately 22 acres of land in Greensboro, N.C., to support the Company's future commercial manufacturing needs for REACT ® , its proprietary REnal Autologous Cell Therapy, currently in Phase 3 development for the treatment of diabetic CKD. Under the purchase agreement, ProKidney will pay approximately $25.5 million in cash for the facility and property. The transaction is expected to close by the end of June 2023, subject to customary cl..." |
|
| 05/26/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/26/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/26/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/11/2023 |
8-K
| Quarterly results|
Docs:
|
"ProKidney Reports First Quarter Financial Results and Recent Corporate Highlights WINSTON-SALEM, N.C. – May 11, 2023 – ProKidney Corp. , a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease , today announced financial results for the first quarter ended March 31, 2023, and provided an update on recent corporate developments. “During the first quarter of 2023, we continued to advance the Phase 3 clinical development of REACT® to assess its potential to delay and possibly eliminate the need for dialysis, and in parallel we sharpened our plans for manufacturing and organizational development as we progress toward potential commercialization,” said Dr. Tim Bertram, Chief Executive Officer of ProKidney. “Patient enrollment in proact ..." |
|
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/27/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 04/21/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 04/21/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/17/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 03/28/2023 |
8-K
| Quarterly results |
| 03/28/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/07/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 03/06/2023 |
8-K
| Investor presentation |
| 02/14/2023 |
SC 13G/A
| Sculptor Capital LP reports a 0% stake in PROKIDNEY CORP. |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
SC 13G/A
| MORGAN STANLEY reports a 17.8% stake in PROKIDNEY CORP. |
| 02/09/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/06/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 02/06/2023 |
8-K
| Quarterly results |
| 01/20/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 01/19/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/11/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
|